However, the clinical utility of such drugs is often constrained in tumor cells with high levels of chemotherapeutic drug-induced replications stress, where combination therapy triggers excessive origin firing and RPA exhaustion in S-phase arrested cells, leading to DNA damage and cell death in both tumor and normal tissues44. This evidence concerns the gene RPA1 and neoplasm.